Trial · NCT00439270
Results by group151
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 151
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With a Prostate Specific Antigen (PSA) Response | Dasatinib, 100 mg + Docetaxel, 75 mg/m^2 | 64.7 | 95% Confidence Interval 46.49 to 80.25 | Percentage of participants | |
| Maximum Tolerated Dose (MTD) of Dasatinib Administered With Docetaxel | All Treated (Phase 1) | NA | mg | ||
| Duration of Prostate Specific Antigen (PSA) Response | Dasatinib, 100 mg + Docetaxel, 75 mg/m^2 | 9.5 | 95% Confidence Interval 7.1 to 25.2 | Months | |
| Number of Months of Progression-free Survival (PFS) | Dasatinib, 100 mg + Docetaxel, 75 mg/m^2 | 11.5 | 95% Confidence Interval 8.8 to 18.9 | Months | |
| Percentage of Participants With an Objective Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST) | Dasatinib, 100 mg + Docetaxel, 75 mg/m^2 | 44.1 | 95% Confidence Interval 27.19 to 62.11 | Percentage of participants | |
| Number of Participants by Best On-study Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST) | Dasatinib, 100 mg + Docetaxel, 75 mg/m^2 | Complete response | 0 | Participants | |
| Number of Participants by Best On-study Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST) | Dasatinib, 100 mg + Docetaxel, 75 mg/m^2 | Partial response | 15 | Participants | |
| Number of Participants by Best On-study Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST) | Dasatinib, 100 mg + Docetaxel, 75 mg/m^2 | Stable disease | 1 | Participants | |
| Number of Participants by Best On-study Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST) | Dasatinib, 100 mg + Docetaxel, 75 mg/m^2 | No change | 3 | Participants | |
| Number of Participants by Best On-study Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST) | Dasatinib, 100 mg + Docetaxel, 75 mg/m^2 | Progressive disease | 2 | Participants | |
| Number of Participants by Best On-study Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST) | Dasatinib, 100 mg + Docetaxel, 75 mg/m^2 | Not evaluable | 13 | Participants | |
| Recommended Phase 2 Dose of Dasatinib Administered With Docetaxel, 75 mg/m^2 | All Treated (Phase 1) | 100 | mg | ||
| Number of Participants by Best On-study Bone Scan Assessment From Baseline | Dasatinib, 100 mg + Docetaxel, 75 mg/m^2 | Improved | 8 | Participants | |
| Number of Participants by Best On-study Bone Scan Assessment From Baseline | Dasatinib, 100 mg + Docetaxel, 75 mg/m^2 | Stable | 17 | Participants | |
| Number of Participants by Best On-study Bone Scan Assessment From Baseline | Dasatinib, 100 mg + Docetaxel, 75 mg/m^2 | No change | 7 | Participants | |
| Number of Participants by Best On-study Bone Scan Assessment From Baseline | Dasatinib, 100 mg + Docetaxel, 75 mg/m^2 | Progression | 1 | Participants | |
| Number of Participants by Best On-study Bone Scan Assessment From Baseline | Dasatinib, 100 mg + Docetaxel, 75 mg/m^2 | Not evaluable | 1 | Participants | |
| Percentage of Participants With Improvement on Bone Scan | Dasatinib, 100 mg + Docetaxel, 75 mg/m^2 | 23.5 | 95% Confidence Interval 10.75 to 41.17 | Percentage of participants | |
| Baseline Scores and Changes in Pain Intensity From Baseline on the Brief Pain Inventory Short Form (BPI-sf) Scores Through Cycle 6 | Dasatinib, 100 mg + Docetaxel, 75 mg/m^2 (Phase 2 ) | Baseline: Average of pain (n=18) | 1.0 | Full Range 1.0 to 5.8 | Units on a scale |
| Baseline Scores and Changes in Pain Intensity From Baseline on the Brief Pain Inventory Short Form (BPI-sf) Scores Through Cycle 6 | Dasatinib, 100 mg + Docetaxel, 75 mg/m^2 (Phase 2 ) | Baseline: Average of pain interference (n=18) | 1.0 | Full Range 0.0 to 7.3 | Units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00439270/results